Penny Stock Talk

Want a nice Xmas or New Year's present? Northwest Biotherapeutics is poised for big gains in 30 to 60 days.
Brandon Nelson Nov 09,2020,21:51

Hello, my name is Brandon. I am not from Goldman Sachs or from some top investment bank. I am not a professional analyst.

So, who am I? I am just a novice trader who started with $50 in May 2020 and has banked $22,000 since. I realized I had a gift for discovering big moves in small-cap stocks during this pandemic.

Here is my latest pick: Northwest Biotherapeutics Inc.(OTCMKTS: NWBO)

The play

Current Price: $1.11

Lowest Buy Price (LBP): $1.10

Maximum Sell Price (MSP): $20.00

Multiplier: 18x

Every $100 invested = $1,800 payout

Hold: Less than 60 days, sell near MSP.

The Scoop:

This company recently completed Phase III clinical trial for brain cancer treatment drug, DCVax-L, and the validated results are expected by Nov 22nd. This drug treatment may be the best ever for treating advanced stages of brain cancer. Great results are expected to be released soon.

The Company:

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers.

The Technicals:

Outstanding Share: 731.50 million

Market Cap: $994.84 million

EPS: -0.0870


Disclaimer:

I am not a paid analyst or professional trader. All information that I provide pertaining to the penny stock market is purely educated estimates based on my own research and due diligence. Investing can be very risky and it is up to the investor/stock trader to make good decisions when trading. I am not responsible for your choices.

CapitalWatch Disclaimer
The opinions expressed in this article do not reflect the position of CapitalWatch or its journalists. CapitalWatch has no business relationship with any company whose stock is mentioned in this article. Information provided is for educational purposes only and does not constitute financial, legal, or investment advice

Topics:penny stocks, OTC, small cap
READ MORE
SUBSCRIBERS ONLY
MOST READ
LATEST NEWS